Related references
Note: Only part of the references are listed.Cholinergic and serotonergic modulation of resting state functional brain connectivity in Alzheimer's disease
Bernadet L. Klaassens et al.
NEUROIMAGE (2019)
An anti-nicotinic cognitive challenge model using mecamylamine in comparison with the anti-muscarinic cognitive challenge using scopolamine
Anne Catrien Baakman et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects
Ricardo Alvarez-Jimenez et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Frontal theta activity reflects distinct aspects of mental fatigue
Edmund Wascher et al.
BIOLOGICAL PSYCHOLOGY (2014)
Healthy aging: Relationship between quantitative electroencephalogram and cognition
Milene Roca-Stappung et al.
NEUROSCIENCE LETTERS (2012)
The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects
M. Liem-Moolenaar et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2010)
The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects
M. Liem-Moolenaar et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2010)
Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?
A. K. Wallin et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2009)
Altered verbal working memory process in patients with Alzheimer's disease
Hyun-Kook Lim et al.
NEUROPSYCHOBIOLOGY (2008)
Prediction of response to donepezil in Alzheimer's disease: combined MRI analysis of the substantia innominata and SPECT measurement of cerebral perfusion
Hidekazu Kanetaka et al.
NUCLEAR MEDICINE COMMUNICATIONS (2008)
Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha(2,3) subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers
S. L. de Haas et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2008)
Identification of responders to rivastigmine: A prospective cohort study
Afina W. Lemstra et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2008)
Cognitive predictors of donepezil therapy response in Alzheimer disease
Daniel Saumier et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2007)
Effectiveness of acetylcholinesterase inhibitors: diagnosis and severity as predictors of response in routine practice
Rohan Van Der Putt et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2006)
Cholinesterase inhibitors for Parkinson's disease dementia
I Maidment et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2006)
Functional magnetic resonance imaging response to increased verbal working memory demands among patients with multiple sclerosis
LH Sweet et al.
HUMAN BRAIN MAPPING (2006)
Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation - a pharmacological fMRI study
R Goekoop et al.
BRAIN (2006)
Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer's disease
PJ Connelly et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2005)
Challenging the cholinergic system in mild cognitive impairment: a pharmacological fMRI study
R Goekoop et al.
NEUROIMAGE (2004)
EEG dynamics in patients with Alzheimer's disease
JS Jeong
CLINICAL NEUROPHYSIOLOGY (2004)
The cholinergic lesion of Alzheimer's disease: Pivotal factor or side show?
M Mesulam
LEARNING & MEMORY (2004)
Clinical predictors of response to Acetyl Cholinesterase Inhibitors: experience from routine clinical use in Newcastle
S Pakrasi et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2003)
Regional cerebral blood flow patterns and response to donepezil treatment in patients with Alzheimer's disease
H Hanyu et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2003)
The brainstem control of saccadic eye movements
DL Sparks
NATURE REVIEWS NEUROSCIENCE (2002)
Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease
SARB Rombouts et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2002)
Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease
JVS Gobburu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2001)
A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD
B Winblad et al.
NEUROLOGY (2001)
Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success
B Winblad et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2001)
Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression
MR Farlow et al.
ARCHIVES OF NEUROLOGY (2001)
APOE genotype:: No influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease
J Aerssens et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2001)
Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effects of scopolamine in healthy volunteers
U Ebert et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Responder characteristics to a single oral dose of cholinesterase inhibitor: A double-blind placebo-controlled study with tacrine in Alzheimer patients
O Almkvist et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2001)
Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial
GK Wilcock et al.
BRITISH MEDICAL JOURNAL (2000)
Pharmaco-EEG test dose response predicts cholinesterase inhibitor treatment outcome in Alzheimer's disease
V Knott et al.
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY (2000)
Share Paper
